MN2 Stock Chart & Stats
€1.20
€0.00(0.00%)
At close: 4:00 PM EST
€1.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.80 - €1.42
Previous CloseN/A
Volume0.00
Average Volume (3M)106.00
Market Cap
€34.35M
Enterprise Value€325.16
Total Cash (Recent Filing)€61.07M
Total Debt (Recent Filing)€13.56M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 10, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding28,125,734
10 Day Avg. Volume0
30 Day Avg. Volume106
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)2.71
Price to Sales (P/S)1.34
P/FCF Ratio-14.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€28.97M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained TTM revenue growth indicates improving demand for Mentice’s simulation solutions and expanding customer adoption, supporting operating leverage and providing a foundation for future profitability if growth continues.
Low LeverageConservative leverage reduces financial risk and interest pressure, giving Mentice flexibility to fund product development, customer deployments and commercial expansion without relying heavily on additional borrowing.
Positive Cash GenerationThe return to positive operating and free cash flow improves internal funding capacity and supports business resilience. It also suggests that recent revenue and operational improvements are beginning to translate into liquidity.
Bears Say
Continued Net LossesOngoing operating and net losses show that Mentice has not yet established durable profitability. Until margins improve consistently, growth may require continued cost discipline and could limit reinvestment capacity.
Cash Flow VolatilityUneven cash generation creates uncertainty around the reliability of internally funded growth. Working-capital and execution variability could periodically pressure liquidity even though TTM cash flow has recently improved.
Negative Return On EquityNegative ROE indicates that the substantial equity base is not currently producing positive returns. This weakens capital efficiency and highlights the need for sustained earnings improvement before the balance sheet can generate attractive shareholder returns.
Mentice AB News
MN2 FAQ
What was Mentice AB’s price range in the past 12 months?
Mentice AB lowest stock price was €0.80 and its highest was €1.42 in the past 12 months.
What is Mentice AB’s market cap?
Mentice AB’s market cap is €34.35M.
When is Mentice AB’s upcoming earnings report date?
Mentice AB’s upcoming earnings report date is Nov 10, 2026 which is in 71 days.
How were Mentice AB’s earnings last quarter?
Mentice AB released its earnings results on Jul 23, 2026. The company reported -€0.001 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.008.
Is Mentice AB overvalued?
According to Wall Street analysts Mentice AB’s price is currently Overvalued.
Does Mentice AB pay dividends?
Mentice AB does not currently pay dividends.
What is Mentice AB’s EPS estimate?
Mentice AB’s EPS estimate is >-0.01.
How many shares outstanding does Mentice AB have?
Mentice AB has 28,125,734 shares outstanding.
What happened to Mentice AB’s price movement after its last earnings report?
Mentice AB reported an EPS of -€0.001 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went up 4.367%.
Which hedge fund is a major shareholder of Mentice AB?
Currently, no hedge funds are holding shares in DE:MN2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mentice AB
Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.
Technical Analysis
Getinge
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Scandinavian Real Heart AB
―



